Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/11/26 | 8-K | Current report |
|
  |
7 |
| 06/10/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/10/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/10/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/10/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/10/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/05/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 06/04/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 06/03/26 | 8-K | Current report |
|
|
61 |
| 06/01/26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 |
